<DOC>
	<DOCNO>NCT00305084</DOCNO>
	<brief_summary>The main objective trial document safety combination ( escalation dose NGR-hTNF , 0.2 mcg/sqm 1.6 mcg/sqm , fix dose doxorubicin , 75 mg/sqm ) . Safety establish clinical laboratory assessment accord National Cancer Institute Common Toxicity Criteria ( NCI-CTC ) .</brief_summary>
	<brief_title>Study NGR-hTNF Combination With Doxorubicin Solid Tumors</brief_title>
	<detailed_description>This phase IB , open-label , non-randomized , dose-escalation study conduct sequential cohort patient . Three patient per cohort plan . Patients , advance metastatic solid tumor previously treat non cumulative dose doxorubicin ( &lt; 300 mg/sqm order allow adequate number cycle ) chemotherapy naïve enrol .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients ≥18 year old proven advance metastatic solid tumor amenable clinical improvement current standard treatment previously treat non cumulative dose anthracyclines ( &lt; 300 mg/sqm ) chemotherapy naïve . Life expectancy 3 month . ECOG performance status 0 2 . Normal cardiac function ( left ventricular ejection fraction [ LVEF ] ≥55 % ) absence uncontrolled hypertension . Absence condition involve hypervolemia consequence . Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2 x ULN Serum creatinine &lt; 1.5 x ULN Patients may prior therapy provide follow condition meet : Chemo , radio , hormonal , immuno antivascular therapy : washout period 28 day . Surgery : washout period 14 day . Patients must give write informed consent participate study . Concurrent anticancer therapy Patients must receive investigational agent study Patients LVEF &lt; 55 % New York Heart Association class III IV cardiac disease Acute angina Patients myocardial infarction within last six ( 6 ) month Patient significant peripheral vascular disease Thrombosis main portal vein Previous sign severe toxicity doxorubicin relate Previous sign cardiotoxicity doxorubicin related Patients previously treat cumulative dosage anthracyclines ≥300 mg/m^2 Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>solid tumor</keyword>
</DOC>